| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_16ddaeca2a2bf02279f23e6b474e69f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e0f4f8190960626ec922a1f03bcd4aba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d96b9c5efb8d0fa8cb707b5096ced886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c377d69b98d2bd0c07e7c0c0008f0e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb08ced69f512e0b68abaf37fade78ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e62bdc77d40d2d09c7ede7712bd6597
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3f2ad50916cd1328b80e52f8972d0e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d08a8a926edb10b83cae280358c4e14c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-00 |
| filingDate |
2005-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eea7f094efe5ad258f28527b67dae1f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6a9156ee0dfff6108865ed568e8a975
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c9b7bfd9b6ecab831ebde86960c2919
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24bbf3d06bf16749bd80fbbd6a1c9c9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96ef7536519e3a12e6f74fe7cac51ff1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af7986d926839af99c28041d7546999a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f33eeb8cea7ac4b1f3290cce157de3c9 |
| publicationDate |
2006-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006013445-A2 |
| titleOfInvention |
Thiazolidinedione derivatives as alpha adrenergic receptor antagonists |
| abstract |
The present invention relates to alpha 1a and/or alpha 1d adrenergic receptor antagonists. Compounds described can function as alpha 1a and/or alpha 1d adrenergic receptor antagonists and can be used to treat diseases or disorders mediated through alpha 1a and/or alpha 1d adrenergic receptors. Compounds described can also be used to treat benign prostatic hyperplasia or related symptoms thereof. Compounds described can also be used to treat lower urinary tract symptoms associated with or without benign prostatic hyperplasia. Also described are processes to prepare the described compounds, as well as pharmaceutical compositions thereof and methods of treating benign prostatic hyperplasia or related symptoms thereof. |
| priorityDate |
2004-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |